Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.021x

Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥61.35 Million ≈ $8.98 Million USD) by net assets (CN¥2.87 Billion ≈ $419.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Chengdu Easton Biopharmaceuticals Co Ltd net asset quality index to measure how much of total assets are equity-financed.

Chengdu Easton Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Chengdu Easton Biopharmaceuticals Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Altus Group Limited TO:AIF	0.052x
Dole plc F:4CB	0.064x
Aavas Financiers Limited NSE:AAVAS	-0.025x
Sarawak Oil Palms Bhd KLSE:5126	0.045x
Genius Sports Ltd NYSE:GENI	-0.090x
Guangzhou Newlife New Material Co. Ltd. A SHE:301323	N/A
Beijing Shunxin Agriculture Co Ltd SHE:000860	0.019x
Harbin Electric Coporation Jiamusi Electric Machine Co Ltd SHE:000922	0.028x

Annual Cash Flow Conversion Efficiency for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 688513 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥6.66 Billion ≈ $975.13 Million	CN¥264.94 Million ≈ $38.77 Million	0.040x	-59.25%
2024-12-31	CN¥2.70 Billion ≈ $394.79 Million	CN¥263.24 Million ≈ $38.52 Million	0.098x	-7.71%
2023-12-31	CN¥2.60 Billion ≈ $380.96 Million	CN¥275.25 Million ≈ $40.28 Million	0.106x	+70.09%
2022-12-31	CN¥2.44 Billion ≈ $357.70 Million	CN¥151.94 Million ≈ $22.23 Million	0.062x	-3.49%
2021-12-31	CN¥2.29 Billion ≈ $335.34 Million	CN¥147.60 Million ≈ $21.60 Million	0.064x	-13.79%
2020-12-31	CN¥2.10 Billion ≈ $306.60 Million	CN¥156.52 Million ≈ $22.90 Million	0.075x	-63.26%
2019-12-31	CN¥697.44 Million ≈ $102.06 Million	CN¥141.83 Million ≈ $20.75 Million	0.203x	-29.02%
2018-12-31	CN¥582.19 Million ≈ $85.19 Million	CN¥166.79 Million ≈ $24.41 Million	0.286x	+48.85%
2017-12-31	CN¥445.28 Million ≈ $65.16 Million	CN¥85.70 Million ≈ $12.54 Million	0.192x	-29.27%
2016-12-31	CN¥389.79 Million ≈ $57.04 Million	CN¥106.06 Million ≈ $15.52 Million	0.272x	+44.32%
2015-12-31	CN¥268.21 Million ≈ $39.25 Million	CN¥50.57 Million ≈ $7.40 Million	0.189x	-17.97%
2014-12-31	CN¥203.25 Million ≈ $29.74 Million	CN¥46.71 Million ≈ $6.84 Million	0.230x	+37.82%
2013-12-31	CN¥168.62 Million ≈ $24.67 Million	CN¥28.12 Million ≈ $4.11 Million	0.167x	--

About Chengdu Easton Biopharmaceuticals Co Ltd

SHG:688513 China Biotechnology

Market Cap

$1.18 Billion

CN¥8.06 Billion CNY

Market Cap Rank

#8193 Global

#1898 in China

Share Price

CN¥45.66

Change (1 day)

+0.26%

52-Week Range

CN¥41.53 - CN¥79.60

All Time High

CN¥79.60